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Abstract
From December 2000 until 2010, the researchers at Royan Institute conducted a wide range 
of investigations on ovarian tissue cryopreservation with the intent to provide fertility pres-
ervation to cancer patients that were considered to be candidates for these services. In 2010, 
Royan Institute established the Royan Human Ovarian Tissue Bank as a subgroup of the 
Embryology Department. Since its inception, approximately 180 patients between the ages 
of 7- 47 years have undergone consultations. Ovarian samples were cryopreserved from 47 
patients (age: 7-35 years) diagnosed with cervical adenocarcinoma (n=9); breast carcinoma 
(n=7), Ewing’s sarcoma (n=7), opposite side ovarian tumor (n=7), endometrial adenocarci-
noma (n=4), malignant colon tumors (n=3), as well as Hodgkin’s lymphoma, major thalas-
semia and acute lymphoblastic leukemia (n=1-2 patients for each disease). Additionally, 
two patients requested ovarian tissue transplantation after completion of their treatments.      
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There is a concerning increase in cancer diagnoses 
according to the Iranian Cancer Society. Today, due 
to medical advances, many cancers are treatable with 
timely diagnosis and follow up. The patient can re-
turn to a normal life after radiotherapy, chemothera-
py, or surgical tumor excision. Therefore, many can-
cers are no longer considered incurable. Although, in 
many cases, chemotherapy and radiotherapy aim to 
save lives, premature ovarian failure and reduction of 
follicular reserve is undeniable. By taking into con-
sideration the probable infertility of cancer patients, 
preservation of their reproductive ability prior to 
onset of cancer treatment is crucial (1, 2). Different 
methods of assisted reproductive techniques that in-
clude oocyte, embryo and ovarian tissue cryopreser-
vation have helped these patients. The use of these 
techniques in single or married, as well as young 
and older women differ. Hence, the most appropriate 
technique is selected according to the patients’ cir-
cumstances (1-7). In cases where adequate time exists 
for ovarian stimulation, embryo cryopreservation is 
considered the gold standard and an acceptable clini-
cal technique. However, if embryo cryopreservation 
is not an option due to the absence of a sexual partner, 
unwillingness to use donor sperm, or for any other 
reason, the oocytes can be frozen (6). Ovarian tissue 
cryopreservation is another technique that has a long 
history of use, but with a new purpose. Limitations 
of oocyte cryopreservation exist, such as the impos-
sibility of stimulating ovaries in patients with hyper-
stimulation syndrome. Under these circumstances, 
ovarian tissue cryopreservation is more accepted and 
approved (2, 5). In this technique numerous follicles 
at different stages of maturity are preserved without 
delays to cancer treatment. In addition, for single or 
young girls this is the best choice to preserve their 
reproductive ability (3, 4). 
The Royan Human Ovarian Tissue Bank was es-
tablished in 2010 with the intent to provide fertility 
preservation services to cancer patients eligible for 
preservation of reproductive ability. We have estab-
lished the maximum age for inclusion in the Tissue 
Bank as 35 years. Cases of malignancy where tu-
mors have metastasized to the ovarian tissue are not 
accepted for cryopreservation. In other cases there is 
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no exclusion for acceptance. Patients undergo an ini-
tial consultation that determines individual factors of 
age, marital status, physical and mental conditions, 
cancer type, its progression stage and grade, level of 
previous treatments, earlier infertility treatment and 
prognosis after treatment. After the initial consulta-
tion, the best fertility preservation technique is se-
lected. A contract is signed between the Ovarian Tis-
sue Bank and the patient after the consultation. This 
contract includes patients’ rights and sample mainte-
nance insurance, as well as informing patients about 
the use of her own sample after treatment, which is 
approved by the Royan Ethical Committee. 
The procedure for ovarian tissue cryopreserva-
tion at the Royan Human Ovarian Tissue Bank is as 
follows. An ovarian tissue sample is removed from 
the patient by laparoscopy, laparotomy, unilateral 
or bilateral oophorectomy according to the patient’s 
condition. The sample is transferred to the Ovarian 
Bank in the shortest possible time (approximately 
1 hour) in Medium 199+Heppes (HTCM, Gibco, 
Paisley, UK)+20% human serum albumin (HAS, 
Biotest, Germany) as transfer medium at 4°C and 
on ice. In the laboratory, initially, the transferred 
tissue is washed in HTCM+20% HSA medium, 
after which the medullary part is removed. Next, 
the cortical part is thinned and 10×5×1 mm strips 
are obtained from the thin cortex. These steps are 
all performed on a cool pad. Finally, the stripes are 
vitrified in a two-step process, equilibration and 
vitrification. In the first step (equilibration), each 
strip is washed in equilibrium medium composed 
of HTCM, ethylene glycol (EG, Sigma, St. Louis, 
MO, USA), Dimethyl sulphoxide (DMSO, Sigma, 
USA, each 7.5%) and 20% HSA for 15 minutes at 
4°C. In the second step (vitrification), each strip 
is washed in 15% HTCM, 15% DSMO and 15% 
EG, 0.25 M sucrose, and 20% HSA for 10 minutes 
at 4°C. The extra medium is completely removed 
from the strips, after which they are directly trans-
ferred into liquid nitrogen. Of note, we randomly 
fix one strip before cryopreservation for histologi-
cal evaluation (H&E staining and Semi thin). For 
tissue evaluation, one vitrified strip is warmed and 
assessed histologically. Warming is performed in 
4 steps in descending concentrations (1, 0.5, 0.25, 
and 0.125) of sucrose. The base medium is com-
prised of HTCM+20% HSA. The histological as-
sessment markers considered for tissue evaluation 
include total integrity, follicular population, oo-
cyte degeneration, vacuolization and granulation 
of the nucleus, oolemma and ooplasm conditions, 
zona pellucida situation (in secondary or preantral 
follicle), coherence and connectivity of granulosa 
cells (Fig.1). 
Fig.1: Primordial (short arrows), primary (long arrows) and preantral (black arrow) follicles in A., B., C. Control, D., E. and F. Vitrified hu-
man ovarian tissues. Hematoxylin and eosin (H&E) staining (magnification: ×20, ×50 μm).
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Functionality of the entire ovarian tissue is con-
sidered by the presence or absence of the corpus 
luteum or corpus albicans in tissue. Finally, the in-
formation is kept and filed in a histology descrip-
tion form.
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